FloraGlo at 30: How lutein science moved beyond eye health

Thirty years after FloraGlo lutein entered the market, the science has expanded well beyond its eye-health foundations. From cognition and early-life nutrition to the emerging potential of zeaxanthin, Kemin sees new opportunities to take lutein across life stages and into the digital age.

Lutein and zeaxanthin are sometimes referred to as macular carotenoids since both are concentrated in the macula in the eye. The macula is a yellow spot of about five millimeters diameter on the retina (lutein and zeaxanthin are the source of the yellow color).

While the link between lutein and zeaxanthin and eye health was first reported in 1994 by Dr Johanna Seddon and her co-workers at Harvard University, who found a link between the intake of carotenoid-rich food, particularly dark green leafy vegetables like spinach, and a significant reduction in age-related macular degeneration (AMD) (JAMA), Kemin was in the lutein game earlier than this because of the inclusion of marigold meal in chicken feed.

A big early breakthrough was Kemin patenting the production of pure crystallized lutein.

“This actually was the genesis of all of this, where all of this began because Kemin was the first company to be able to bring free lutein to the marketplace,” said Joanne Lasrado, VP of global carotenoids for Kemin Human Nutrition and Health.

Building an evidence base for FloraGlo

This crystallized lutein provided researchers with a reference product to explore the potential benefits of lutein and zeaxanthin, and today FloraGlo has been used in over 130 clinical trial publications, said Lasrado.

“While Kemin invested in the science ourselves, Kemin has also been a fantastic partner for researchers over the last 30 years by just giving free product to anyone that wanted to study it,” she said.

Explore related questions

Inclusion of lutein and zeaxanthin in the AREDS2 formula was a significant milestone, with data published in 2013 showing that the expanded formula was associated with a statistically significant reduction in the progression to advanced AMD of 18%, compared to the original AREDS supplement (vitamins C, E, beta-carotene and zinc).

The original focus for many researchers was around age-related macular degeneration (AMD) but the benefits also extend to healthy vision around contrast sensitivity and photo stress recovery, said Lasrado.

Age-related eye issues remain the main driver for lutein and zeaxanthin, but there have been notable scientific advances around the potential cognitive health benefits of the carotenoids.

Early studies in primates, and more recently in children, middle-aged people and the elderly now support the importance of lutein in brain health, which is unsurprising given that the eyes and the brain are connected.

Indeed, findings from pediatric brain tissue studies have shown that about 60% of the total carotenoids in the pediatric brain tissue is lutein, and yet NHANES data show that lutein represents only about 12% of carotenoids in the diet, showing an apparent preference for lutein in the brain (Vishwanathan et al. J Pediatr Gastroenterol Nutr. 2014).

“Obviously, they [lutein and zeaxanthin] accumulate in areas of the brain that are related to vision, but they also accumulate in areas related to memory as well,” said Lasrado.

She added that the mechanisms of action are still being investigated. The carotenoids are antioxidants and they are anti-inflammatory, and data suggests they also work better with DHA omega-3s.

Lutein/ zeaxanthin and the quest for a DRI

Despite decades of science, lutein and zeaxathin remain underrepresented in multivitamin formulations, said Lasrado.

“I would say less than 10% of multivitamins include lutein and zeaxanthin,” she said. “I think there are lots of reasons for that, but because lutein and zeaxanthin do not have DRIs [dietary reference intakes]. It makes it difficult sometimes to get to that place of having that discussion on why it’s important. It doesn’t get called out on a nutrition label, even if it is called out on a supplement facts panel. So, you also have that issue.”

Calls for a DRI for lutein are not new: An analysis published in 2017 in the European Journal of Nutrition concluded that the carotenoid had enough scientific evidence for it to have its own DRI, while Prof. Jeffrey Blumberg, former director of the Antioxidants Research Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts, told NutraIngredients in 2013: “I tell my grad students that I think lutein is a vitamin.”

Lasrado said the DRI/ vitamin conversation is interesting and is gaining momentum, and she is hopeful that this will happen in the future. “I don’t think the near future, if I’m honest,” she added.

What’s next?

With 30 years of a spotlight on lutein, Lasrado and Kemin are increasingly excited about zeaxanthin, the other macula carotenoid that has often been in lutein’s shadow.

“Zeaxanthin actually has a separate identity from lutein,” she said. “It distributes differently. It’s present differently. How it orients itself is different than lutein. The wavelength is different than lutein. Now there overlaps, which is absolutely true, but they’re complementary but different. And I think there’s a lot of work to be done on zeaxanthin, and I think zeaxanthin might turn out to be something extra special, so we are also investing on a lot of zeaxanthin research as well, so that it gets its time in the sun, so to speak, just like lutein.”